<code id='4DFDDA02D9'></code><style id='4DFDDA02D9'></style>
    • <acronym id='4DFDDA02D9'></acronym>
      <center id='4DFDDA02D9'><center id='4DFDDA02D9'><tfoot id='4DFDDA02D9'></tfoot></center><abbr id='4DFDDA02D9'><dir id='4DFDDA02D9'><tfoot id='4DFDDA02D9'></tfoot><noframes id='4DFDDA02D9'>

    • <optgroup id='4DFDDA02D9'><strike id='4DFDDA02D9'><sup id='4DFDDA02D9'></sup></strike><code id='4DFDDA02D9'></code></optgroup>
        1. <b id='4DFDDA02D9'><label id='4DFDDA02D9'><select id='4DFDDA02D9'><dt id='4DFDDA02D9'><span id='4DFDDA02D9'></span></dt></select></label></b><u id='4DFDDA02D9'></u>
          <i id='4DFDDA02D9'><strike id='4DFDDA02D9'><tt id='4DFDDA02D9'><pre id='4DFDDA02D9'></pre></tt></strike></i>

          explore

          explore

          author:fashion    Page View:26
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          knowledge

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          FDA early review: GLP
          FDA early review: GLP

          SarahSilbiger/GettyImagesApreliminaryevaluationbytheFoodandDrugAdministrationdidnotfindevidencethatG

          read more
          The Supreme Court will review a ruling striking down a domestic violence federal gun ban
          The Supreme Court will review a ruling striking down a domestic violence federal gun ban

          WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

          read more

          American taxpayers paid $1.8 trillion in health care costs in 2022

          AdobeAmericantaxpayersfootedthebillforatleast$1.8trillioninfederalandstatehealthcareexpendituresin20